● pepmg Research Desk · Peer-reviewed evidence review
What the research says about AICAR
A neutral summary of the peer-reviewed literature on AICAR, an AMPK-activating small molecule studied as an experimental exercise-mimetic in cell and animal models. Research use only.
Preclinical only — Animal or in-vitro studies only — no controlled human trials. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- AICAR (also called acadesine or AICA riboside) is a small molecule widely used in laboratories as an activator of AMP-activated protein kinase (AMPK), a master regulator of cellular energy metabolism [1].
- It has been studied as an experimental exercise-mimetic and metabolic agent, but the evidence is preclinical: the efficacy findings come from cell cultures and animal models, not controlled human trials [1][6].
- A systematic review cautions that many effects attributed to AICAR are actually AMPK-independent, which complicates interpreting AICAR-based studies [1].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What AICAR is
AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) is described in the literature as one of the most commonly used pharmacological activators of AMP-activated protein kinase (AMPK), the enzyme that senses cellular energy status and regulates metabolism [1]. Much of the early understanding of AMPK biology was built on studies that used AICAR as the activating tool [1].
It is sold as a research chemical. This page summarizes the published preclinical research; material from third-party vendors is offered for laboratory and research use only and is not a medicine for any condition.
What the preclinical research has measured
Preclinical onlyThe metabolic work is largely in rodents and cells. In mice fed a high-fat diet, AICAR attenuated adipose-tissue inflammation, partially restored glucose tolerance, and reduced markers of hepatic steatosis and kidney disease, with the authors noting parallel anti-inflammatory effects in explants of human adipose tissue tested outside the body [3]. In other mouse studies, AICAR reduced diet-induced fatty liver and modulated AMPK, mTOR, and FOXO3 signaling [4].
AICAR has been framed as an exercise-mimetic. A 2024 study in mouse models of diabetic polyneuropathy reported that AICAR prevented and reversed nerve dysfunction and increased AMPK phosphorylation and mitochondrial respiration in sensory-neuron mitochondria [6]. Other animal work reported cardioprotection against doxorubicin-induced heart failure in rats [5], and cell studies examined AICAR's metabolic effects in tissues such as testicular Sertoli cells [2] and its ability to induce programmed necrosis in cultured prostate-cancer cell lines [7].
Across this literature there are no controlled human efficacy trials. A systematic review further cautions that a growing number of AICAR effects previously attributed to AMPK activation are in fact AMPK-independent, calling for care in interpreting AICAR-based studies [1].
What the studies report on safety and adverse events
Preclinical onlyBecause the AICAR research summarized here is preclinical, there is no controlled human safety dataset to report. The cell and animal studies describe pharmacological effects on metabolism and, in cancer-cell work, direct cytotoxicity such as AICAR-induced programmed necrosis in prostate-cancer lines [7], but these are laboratory observations rather than tolerability data in people.
The systematic review's central caution is interpretive rather than a specific toxicity: because AICAR acts through both AMPK-dependent and AMPK-independent pathways, its biological effects are harder to predict and attribute [1].
No human safety conclusions can be drawn from this evidence base. This is not medical advice; consult a qualified professional and read the studies directly.
How strong is the evidence
The evidence is characterized as preclinical: AICAR's metabolic and exercise-mimetic effects have been measured in cell cultures and animal models, with no controlled human efficacy trials in this evidence base [1][3][6]. "Preclinical" describes where the research sits, not a verdict that AICAR does or does not work, and animal findings frequently fail to translate to humans.
Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 7
- AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review.
- The AMP-activated protein kinase activator AICAR regulates lactate production in rat Sertoli cells.
- AICAR ameliorates high-fat diet-associated pathophysiology in mouse and ex vivo models, independent of adiponectin.
- AMPK activation by AICAR reduces diet induced fatty liver in C57BL/6 mice.
- AICAR confers prophylactic cardioprotection in doxorubicin-induced heart failure in rats.
- Administration of AICAR, an AMPK Activator, Prevents and Reverses Diabetic Polyneuropathy by Regulating Mitophagy.
- AICAR induces AMPK-independent programmed necrosis in prostate cancer cells.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.